CAPItello-280: Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Sponsor

AstraZeneca (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05348577

Collaborator

(none)

790

Enrollment

204

Locations

Arms

51.9

Anticipated Duration (Months)

3.9

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall survival is defined as the time from randomization until the date of death due to any cause.

Condition or Disease	Intervention/Treatment	Phase
Prostate Cancer	Drug: capivasertib Drug: docetaxel Other: placebo Drug: docetaxel	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

790 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Approximately 1000 participants will be enrolled and screened to achieve a total of approximately 790 assigned in a 1:1 ratio to one of the two parallel groups to receive either capivasertib or placebo, in combination with docetaxel on a background of ADT for the duration of the study.Approximately 1000 participants will be enrolled and screened to achieve a total of approximately 790 assigned in a 1:1 ratio to one of the two parallel groups to receive either capivasertib or placebo, in combination with docetaxel on a background of ADT for the duration of the study.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

The study is double-blinded, neither the patients nor the investigator will know what study intervention was assigned. Capivasertib and placebo film-coated tablets will be identical in appearance and presented in the same packaging to ensure blinding of the capivasertib. All personnel involved with the statistical analysis of the study will remain blinded until database lock and CSP deviations have been identified.

Primary Purpose:

Treatment

Official Title:

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Actual Study Start Date :

Mar 25, 2022

Anticipated Primary Completion Date :

Jul 22, 2026

Anticipated Study Completion Date :

Jul 22, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: capivasertib + docetaxel Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.	Drug: capivasertib 320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment. Drug: docetaxel Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
Placebo Comparator: placebo + docetaxel Participants receive placebo in combination with docetaxel and steroids on a background of ADT.	Other: placebo matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment. Drug: docetaxel Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

Arm

Intervention/Treatment

Experimental: capivasertib + docetaxel

Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.

Drug: capivasertib

320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

Drug: docetaxel

Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

Placebo Comparator: placebo + docetaxel

Participants receive placebo in combination with docetaxel and steroids on a background of ADT.

Other: placebo

matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

Drug: docetaxel

Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

Outcome Measures

Primary Outcome Measures

Overall Survival (OS) [up to approximately 52 months]
Overall survival is defined as time from randomisation until the date of death due to any cause.

Secondary Outcome Measures

Radiographic Progression-free Survival (rPFS) [up to approximately 40 months]
Radiographic Progression-free Survival (rPFS) is defined as time from randomization to radiographic progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for soft tissue and/or Prostate Cancer Working Group 3 (PCWG3) for bone or death due to any cause
Time to pain progression (TTPP) [up to approximately 40 months]
Time to pain progression (TTPP) based on a 2-point increase from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Item 3 'pain at its worse in the last 24 hours' score (scale from 0 ["no pain"] to 10 ["pain as bad as you can imagine"]) and/or initiation of/increase in opioid analgesic use.
Time to first Symptomatic Skeletal-Related Event (SSRE) [up to approximately 52 months]
SSRE is defined as time from randomisation until any of the following: use of radiation therapy to prevent or relieve skeletal symptoms; Occurrence of new symptomatic pathological bone fractures; Occurrence of spinal cord compression; Orthopaedic surgical intervention for bone metastasis
Time to deterioration in urinary symptoms (TTDUS) [up to approximately 40 months]
Time to deterioration in urinary symptoms (TTDUS) is defined as time from randomization until the change from baseline reaches a clinically meaningful deterioration threshold using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Prostate Questionnaire Urinary Symptoms (QLQ-PR25 (US)) subscale score, where the question responses are provided on a numerical rating scale ranging from 1 ("not at all") to 4 ("very much").
Time to deterioration in Physical Functioning (TTDPF) [up to approximately 40 months]
Time to deterioration in Physical Functioning (TTDPF) is defined as the time from randomization until the change from baseline reaches a clinically meaningful deterioration threshold using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Physical Functioning (QLQ-C30 PF) subscale score, where the question responses are provided on a numerical rating scale ranging from 1 ("not at all") to 4 ("very much").
Overall Pain Severity and Pain Interference as assessed by BPI-SF questionnaire [up to approximately 40 months]
Change from baseline in Brief Pain Inventory-Short Form (BPI-SF) pain at its worse in the last 24 hours score (scale from 0 ["no pain"] to 10 ["pain as bad as you can imagine"]), pain severity (the mean of the four pain severity items each of which ranges from 0 ["no pain"] to 10 ["pain as bad as you can imagine"]) and interference domain scores (the mean of the seven pain interference items each of which ranges from 0 ["does not interfere"] to 10 ["completely interferes"]).
Plasma concentration of capivasertib derived from a population PK model [pre dose (up to 90 minutes prior) and post dose (1 hour, 2 hours and 4 hours post dose)]

Other Outcome Measures

Systolic and diastolic blood pressure [Up to approximately 52 months]
millimetre of mercury (mmHg)
Pulse rate (heart rate) [Up to approximately 52 months]
Beats per minute (BPM)
Body Temperature [Up to approximately 52 months]
Celsius (°C)
Weight [Up to approximately 52 months]
Kilograms (kg)
The number of participants with adverse events [Up to approximately 52 months]
Data will include clinical observations, ECG parameters, clinical chemistry / haematology / glucose metabolism parameters and vital signs assessed as the number of participants with adverse events.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 130 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically-confirmed prostate adenocarcinoma without neuroendocrine or small cell cancers
Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion (defined as 1 lesion with positive uptake on bone scan) and/or ≥ 1 soft tissue lesion (measurable or non-measurable)
Patient must have been previously treated with a next generation hormonal agent (NHA), ie, abiraterone, enzalutamide, apalutamide or darolutamide, for prostate cancer for at least 3 months and shown evidence of disease progression (radiological or via PSA assessment) while receiving the NHA
Evidence of mCRPC with progression of disease despite androgen deprivation therapy (ADT) and after anti-androgen withdrawal if applicable
Serum testosterone level ≤ 50 ng/dL
Candidate for docetaxel and steroid therapy
Ongoing ADT with LHRH agonist, LHRH antagonist, or bilateral orchiectomy
Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1 and anticipated minimum life expectancy of 12 weeks
Confirmation that archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample which meets the minimum pathology and sample requirements is available to send to the central laboratory
Able and willing to swallow and retain oral medication
Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion Criteria:

Radiotherapy with a wide field of radiation within 4 weeks before start of study treatment
Major surgery (excl. placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, internal stents) within 4 weeks of start of study treatment
Brain metastases,or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment)
Any of the following cardiac criteria:

Mean resting corrected QT interval (QTc) >470 msec from 3 consecutive ECGs ii. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG

Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age,or any concomitant medication known to prolong the QT interval iv. Experience of any of the following procedures or conditions in the preceding 6months: coronary artery bypass graft, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥2 v. Uncontrolled hypotension - systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg vi. Cardiac ejection fraction outside institutional range of normal or <50% (whichever is higher) as measured by echocardiogram (or multiple-gated acquisition scan if an echocardiogram cannot be performed or is inconclusive)

Clinically significant abnormalities of glucose metabolism as defined by any of the following:

Patients with diabetes mellitus (DM) type 1 or DM type 2 requiring insulin treatment ii. HbA1c ≥8.0% (63.9 mmol/mol)

Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

Absolute neutrophil count < 1.5x 10^{9/L ii. Platelet count < 100x 10}9/L iii. Haemoglobin < 9 g/dL (< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or > 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin > 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance < 50 mL/min per the Cockcroft and Gault formula without the need for chronic dialysis;

As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant and active bleeding diseases), which, in the investigator's opinion, makes it undesirable for the patient to participate in the study or that would jeopardise compliance with the protocol.
Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent.
Previous allogeneic bone marrow transplant or solid organ transplant
History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy.
Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy, excluding alopecia. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss) after consultation with the medical monitor
Known to have active hepatitis infection, positive hepatitis C antibody, hepatitis B virus surface antigen, or hepatitis B virus core antibody at screening.
Known to have human immunodeficiency virus (HIV) with a CD4+ T-cell count < 350 cells/uL or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months.
Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
Treatment with any of the following:

Prior chemotherapy for CRPC. Chemotherapy for metastatic or localized HSPC (including docetaxel) is allowed provided that chemotherapy was completed ≥ 6months before randomisation and progression of the prostate cancer occurred ≥ 6months after the completion of therapy.

Prior exposure to AKT inhibitors or PI3K inhibitors iii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iv. Any other immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents (except ADT) within 3 weeks of the first dose of study treatment v. Strong inhibitors or inducers of cytochrome P450 (CYP)3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to inhibition of CYP3A4 within 1 week prior to the first dose of study treatment

Drugs known to prolong the QT interval within 5 half-lives of the first dose of study treatment
History of hypersensitivity to active or inactive excipients of capivasertib, docetaxel, or drugs with a similar chemical structure or class
Any restriction or contraindication based on the local prescribing information that would prohibit the use of docetaxel

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Phoenix	Arizona	United States	85004
2	Research Site	Beverly Hills	California	United States	90211
3	Research Site	Fresno	California	United States	93701
4	Research Site	Los Angeles	California	United States	90095
5	Research Site	Sacramento	California	United States	95817
6	Research Site	San Francisco	California	United States	94115
7	Research Site	Santa Monica	California	United States	90404
8	Research Site	Santa Rosa	California	United States	95403
9	Research Site	Aurora	Colorado	United States	80045
10	Research Site	Lakewood	Colorado	United States	80228
11	Research Site	Orange City	Florida	United States	32763
12	Research Site	Chicago Ridge	Illinois	United States	60415
13	Research Site	Chicago	Illinois	United States	60612
14	Research Site	Baltimore	Maryland	United States	21201
15	Research Site	Minneapolis	Minnesota	United States	55404
16	Research Site	Minneapolis	Minnesota	United States	55416
17	Research Site	Hackensack	New Jersey	United States	07601
18	Research Site	Bronx	New York	United States	10461
19	Research Site	White Plains	New York	United States	10601
20	Research Site	Portland	Oregon	United States	97223
21	Research Site	Bala-Cynwyd	Pennsylvania	United States	19004-1017
22	Research Site	Hershey	Pennsylvania	United States	17033
23	Research Site	Greenville	South Carolina	United States	29605
24	Research Site	Watertown	South Dakota	United States	57201
25	Research Site	Chattanooga	Tennessee	United States	37404
26	Research Site	Nashville	Tennessee	United States	37203
27	Research Site	Austin	Texas	United States	78731
28	Research Site	Dallas	Texas	United States	75235
29	Research Site	Kingwood	Texas	United States	77339
30	Research Site	San Antonio	Texas	United States	78217
31	Research Site	Burlington	Vermont	United States	05405
32	Research Site	Seattle	Washington	United States	98109
33	Research Site	Birtinya		Australia	4575
34	Research Site	Kogarah		Australia	2217
35	Research Site	Miranda		Australia	2228
36	Research Site	North Adelaide		Australia	5000
37	Research Site	Orange		Australia	2800
38	Research Site	Redcliffe		Australia	4020
39	Research Site	Wahroonga		Australia	2076
40	Research Site	Woolloongabba		Australia	4102
41	Research Site	Brasschaat		Belgium	2930
42	Research Site	Gent		Belgium	9000
43	Research Site	Liège		Belgium	4000
44	Research Site	Wilrijk		Belgium	2610
45	Research Site	Yvoir		Belgium	5530
46	Research Site	Cachoeiro de Itapemirim		Brazil	29308-014
47	Research Site	Ijuí		Brazil	98700-000
48	Research Site	Porto Alegre		Brazil	90035-903
49	Research Site	Porto Alegre		Brazil	90110-270
50	Research Site	Porto Alegre		Brazil	90160-093
51	Research Site	Recife		Brazil	50040-000
52	Research Site	Rio de Janeiro		Brazil	22281-100
53	Research Site	Salvador		Brazil	41253-190
54	Research Site	Salvador		Brazil	41820-021
55	Research Site	São José Do Rio Preto - SP		Brazil	15090-000
56	Research Site	São Paulo		Brazil	01221-020
57	Research Site	São Paulo		Brazil	01509-010
58	Research Site	São Paulo		Brazil	04014-002
59	Research Site	Tres Lagoas		Brazil	79601-001
60	Research Site	Halifax	Nova Scotia	Canada	B3H 2Y9
61	Research Site	Oshawa	Ontario	Canada	L1G 2B9
62	Research Site	Toronto	Ontario	Canada	M5G 2M9
63	Research Site	Montreal	Quebec	Canada	H3T 1E2
64	Research Site	Toronto		Canada	M4N 3M5
65	Research Site	Santiago		Chile	7500713
66	Research Site	Santiago		Chile	7500918
67	Research Site	Santiago		Chile	7650568
68	Research Site	Temuco		Chile	4781156
69	Research Site	Vina del Mar		Chile	2520000
70	Research Site	Beijing		China	100021
71	Research Site	Beijing		China	100034
72	Research Site	Beijing		China	100050
73	Research Site	Changchun		China	130012
74	Research Site	Changsha		China	410008
75	Research Site	Changsha		China	410013
76	Research Site	Chengdu		China	610041
77	Research Site	Chongqing		China	400038
78	Research Site	Guangzhou		China	510180
79	Research Site	Hangzhou		China	310000
80	Research Site	Hangzhou		China	310003
81	Research Site	Harbin		China	150040
82	Research Site	Nanchang		China	330019
83	Research Site	Nanjing		China	210008
84	Research Site	Nantong		China	226361
85	Research Site	Ningbo		China	315010
86	Research Site	Shanghai		China	200032
87	Research Site	Shanghai		China	200040
88	Research Site	Shenyang		China	110042
89	Research Site	Shenzhen		China	518035
90	Research Site	Tianjin		China	300052
91	Research Site	Wuhan		China	430030
92	Research Site	Wuhan		China	430079
93	Research Site	Yantai		China	264000
94	Research Site	Zhengzhou		China	450008
95	Research Site	Horovice		Czechia	268 01
96	Research Site	Hradec Kralove		Czechia	500 05
97	Research Site	Pardubice		Czechia	532 03
98	Research Site	Praha 10		Czechia	10034
99	Research Site	Praha 4		Czechia	14059
100	Research Site	Praha 5		Czechia	150 06
101	Research Site	Bordeaux		France	33076
102	Research Site	Brest		France	29609
103	Research Site	Clermont-Ferrand CEDEX 01		France	63011
104	Research Site	Montpellier		France	34000
105	Research Site	Paris Cedex 05		France	75248
106	Research Site	Paris		France	75014
107	Research Site	Rouen		France	76031
108	Research Site	Saint Herblain Cedex		France	44805
109	Research Site	Saint-Mande		France	94160
110	Research Site	Strasbourg		France	67000
111	Research Site	Vandoeuvre Les Nancy		France	54000
112	Research Site	Villejuif Cedex		France	94805
113	Research Site	Athens		Greece	115 22
114	Research Site	Athens		Greece	155 62
115	Research Site	Chaidari		Greece	124 62
116	Research Site	Marousi		Greece	151 23
117	Research Site	Patras		Greece	26504
118	Research Site	Peiraias		Greece	185 47
119	Research Site	Budapest		Hungary	1097
120	Research Site	Budapest		Hungary	1122
121	Research Site	Budapest		Hungary	1125
122	Research Site	Budapest		Hungary	1145
123	Research Site	Kecskemét		Hungary	6000
124	Research Site	Nyiregyhaza		Hungary	4400
125	Research Site	Szeged		Hungary	6725
126	Research Site	Szolnok		Hungary	5000
127	Research Site	Bikaner		India	334003
128	Research Site	Meerut		India	250001
129	Research Site	Mohali		India	160055
130	Research Site	Nashik		India	422002
131	Research Site	New Delhi		India	110085
132	Research Site	Chiba-shi		Japan	260-8717
133	Research Site	Hirakata-shi		Japan	573-1191
134	Research Site	Hirosaki-shi		Japan	036-8563
135	Research Site	Kanazawa-shi		Japan	920-8641
136	Research Site	Kashihara-shi		Japan	634-8522
137	Research Site	Kawagoe-shi		Japan	350-8550
138	Research Site	Kita-gun		Japan	761-0793
139	Research Site	Kobe-shi		Japan	650-0047
140	Research Site	Kumamoto-shi		Japan	860-0008
141	Research Site	Miyazaki-shi		Japan	889-1692
142	Research Site	Nagano-Shi		Japan	381-8551
143	Research Site	Nagoya-shi		Japan	466-8560
144	Research Site	Nakano-Ku		Japan	164-0001
145	Research Site	Osaka-shi		Japan	541-8567
146	Research Site	Osakasayama-shi		Japan	589-8511
147	Research Site	Sagamihara-shi		Japan	252-0375
148	Research Site	Sapporo-shi		Japan	003-0804
149	Research Site	Tsu-shi		Japan	514-8507
150	Research Site	Wakayama-shi		Japan	641-8510
151	Research Site	Yokohama-shi		Japan	232-0024
152	Research Site	Bukgu		Korea, Republic of	41404
153	Research Site	Busan		Korea, Republic of	602-739
154	Research Site	Goyang-si		Korea, Republic of	10408
155	Research Site	Seoul		Korea, Republic of	03080
156	Research Site	Seoul		Korea, Republic of	05505
157	Research Site	Seoul		Korea, Republic of	06591
158	Research Site	Seoul		Korea, Republic of	120-752
159	Research Site	Seoul		Korea, Republic of	135-720
160	Research Site	Aguascalientes		Mexico	20116
161	Research Site	Cancún		Mexico	77500
162	Research Site	Ciudad de México		Mexico	03840
163	Research Site	Culiacan		Mexico	80230
164	Research Site	Guadalajara		Mexico	44260
165	Research Site	Guadalajara		Mexico	44680
166	Research Site	Mexico		Mexico	04700
167	Research Site	Oaxaca		Mexico	68000
168	Research Site	Den Haag		Netherlands	2545 CH
169	Research Site	Hoofddorp		Netherlands	2134 TM
170	Research Site	Konin		Poland	62-500
171	Research Site	Lodz		Poland	93-513
172	Research Site	Nowa Sol		Poland	67-106
173	Research Site	Opole		Poland	45-061
174	Research Site	Warszawa		Poland	02-781
175	Research Site	Wieliszew		Poland	05-135
176	Research Site	Barcelona		Spain	08003
177	Research Site	Barcelona		Spain	08035
178	Research Site	Barcelona		Spain	08036
179	Research Site	Barcelona		Spain	?08041
180	Research Site	Cordoba		Spain	14004
181	Research Site	Lugo		Spain	27003
182	Research Site	Madrid		Spain	28034
183	Research Site	Madrid		Spain	28040
184	Research Site	Madrid		Spain	28041
185	Research Site	Malaga		Spain	29010
186	Research Site	Sabadell		Spain	08208
187	Research Site	Sevilla		Spain	41013
188	Research Site	Kaohsiung		Taiwan	81362
189	Research Site	Taichung		Taiwan	40044
190	Research Site	Taichung		Taiwan	40447
191	Research Site	Tainan		Taiwan	704
192	Research Site	Tainan		Taiwan	710
193	Research Site	Taipei		Taiwan	10002
194	Research Site	Taipei		Taiwan	11259
195	Research Site	Bristol		United Kingdom	BS2 8ED
196	Research Site	Edinburgh		United Kingdom	EH4 2XU
197	Research Site	Guildford		United Kingdom
198	Research Site	Hackensack		United Kingdom	07601-1963
199	Research Site	Hampstead		United Kingdom	NW3 2QG
200	Research Site	London		United Kingdom	SE1 9RT
201	Research Site	London		United Kingdom	SW7 3RP
202	Research Site	Manchester		United Kingdom	M20 4BX
203	Research Site	Southampton		United Kingdom	SO16 6YD
204	Research Site	Sutton		United Kingdom	SM2 5PT